April 2025 update

The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.

April 17, 2025, Monthly Update

Dr. Jack Jacobs, President of Zhittya Genesis Medicine, Awarded Nevada Bio Organization’s Man of the Year!

On April 2, 2025, at the Nevada Bio Organization Annual Awards Dinner, Dr. Jack Jacobs was honored as Man of the Year for his remarkable 40-year career in biopharmaceutical development. His groundbreaking research has led to the treatment of over 200 Parkinson’s disease patients, many of whom have experienced significant recovery from that horrible disease. Some of these Parkinson’s disease patients attended the dinner event. Dr. Jacobs has also spearheaded clinical studies using FGF-1 to grow new blood vessels in diseased hearts, offering a potential new treatment for the world’s leading cause of death.

Dr. Jacobs’ work extends to stroke recovery, dementia, Alzheimer’s, peripheral artery disease, diabetic foot ulcers, type-2 diabetes, neuropathy, and more. This is an extraordinary legacy of innovation.

The awards dinner drew over 300 attendees, including medical professionals, business leaders, elected officials, and patients, all gathered to celebrate Dr. Jacobs’s achievements. Below is a picture of that event in action:

Here is Dr. Jacobs with his awards trophy, with John Laub and Vika Montano It was a wonderful night for a wonderful man.

Nevada Right to Try Law

1. We have prepared a NevadaBio Project Paper detailing: Nevada, by Enhancing its “Right to Try” law, will create an Economic Boom for Nevada and Medical Benefits for the rest of the World”
2. Economic Growth and Prosperity that Comes from Medical Innovation “Freedom”

At the NevadaBio Annual Dinner, I was invited to speak on an important topic:

How Nevada can create new economic opportunities for its citizens and advance medical innovation.

I believe 80% of biological discoveries from the past 50 years (starting in 1970) remain undeveloped for treating desperately ill patients. For instance, leading research institutions such as the Salk Institute, the Howard Hughes Medical Institute, the National Institute of Health (NIH), and Scripps demonstrated 12 years ago that FGF-1 (the same drug that Zhittya is testing for Parkinson’s disease) can reverse type-2 diabetes in mice. This breakthrough offers hope for the 38 million Americans and hundreds of millions of worldwide sufferers with this horrible disease that type-2 diabetes may be effectively cured. Yet, over a decade later, Big Pharma has shown no known effort to advance this discovery whatsoever.

Zhittya, operating under clearance in the British Virgin Islands, has treated 10 type-2 diabetes patients, all of whom saw their condition reverse rapidly.

Questions remain: How long will this reversal last? 6 months, 6 years, or indefinitely? Is a booster required every 5 years? We are continuing our research to get these questions answered. But where are Big Pharma, major medical institutions, and diabetes charities like the American Diabetes Association (which raised $150 million in 2023) in this effort? Nowhere to be found.

The London School of Economics estimates it takes 18 years and $1 – $2 billion dollars to get a drug approved in the United States. These government-imposed barriers delay medical innovation and condemn many to suffer or die. The Federal “Right to Try” Law, enacted seven years ago, has been used just 18 times in seven years, per Forbes. Its restrictive criteria exclude patients with ALS, cancer, or stage 4 Parkinson’s disease unless they are within a year of certain and assured death, rendering the law completely ineffective. Zhittya’s type-2 diabetes patients, successfully treated abroad, would not qualify under this law, nor would our 200+ Parkinson's’ disease patients that have been treated intranasally (100% safely) or our patients treated for other conditions, including stroke, dementia, autism, and more.

These delays of 7 to 18 years are a death sentence for many. Stage 3 or 4 Parkinson’s disease may not kill directly, but the suffering drives many to suicide and a destruction in the quality of life for these sufferers. Who is the FDA protecting in these horrible situations? Unfortunately, Nevada’s own “Right to Try” Law mirrors the same federal flaws and is equally underutilized.

Zhittya Genesis Medicine, working with NevadaBio, has put forward some ideas to enhance the present law to allow real medical innovation. Patients from Zambia, Bolivia, New Zealand, Saudi Arabia, the Seychelles, and beyond have traveled to the British Virgin Islands for our Parkinson’s disease research. From April 3–6, Vika and I joined John Laub, NevadaBio President, in Carson City (the capital of Nevada) to meet with elected officials, state senators, the Governor, and Lt. Governor, presenting our project plan. We believe an improved law could spark an economic boom surpassing the economic impact of Nevada’s gambling industry. I believe this would draw thousands of sick people to Nevada seeking cutting-edge treatments; rather than enduring decades-long suffering from FDA delays. Here is a photo of us in the Nevada State Capitol:

For a copy of the project plan, click here: https://www.nevbio.org/ Zhittya’s Outreach Program In our March 17, 2025, Update, I introduced our Zhittya Outreach Program, which received strong interest. We had been busy with our April 2 NevadaBio Awards Dinner and could not advance the Outreach program until now. But now that we have successfully completed that event, we are prioritizing our Out Reach Program.

Here is what I wrote last month:

With all the success we are having on our Medical Research Studies, some of our supporters have taken to giving presentations on our medical breakthroughs to their local groups. One of our biggest supporters has prepared a PowerPoint presentation, and then he reached out to local organizations. Not to Parkinson’s disease groups, they will not let us present to their groups for fear of losing their Big Pharma sponsors. The last thing Big Pharma wants is to have someone showing there could be a cure for Parkinson’s disease. He has been invited to several women’s groups who have monthly meetings and are looking for interesting speakers. He gave one presentation at a Las Vegas event with 130 attendees and a great response. Many attendees have loved ones who want to share what we have accomplished. It has been a wonderful response, and the groups he has talked to want him to come back and give follow-up presentations on our progress.

Many of Zhittya’s Lab Rats (a term of endearment) have asked many times, “How can I get the world to know that this is real?”. We have had medical doctors who own a clinic, who would like to give a presentation in their area to educate people on new medical therapies coming for those diseases that have no present treatment, diseases like Parkinson’s disease, dementia, Alzheimer’s disease, neuropathy, severe diabetic foot ulcers, chronic leg ischemia, and more. We have been contacted by clinics in Germany, Japan, the Arab world, and several in the United States in the last month who want to reach out to their community and show people they may have something different for patients, if not today, then maybe next year. One medical doctor advertised his presentation: “Parkinson’s Disease: Is there a treatment that can reverse this disease?” He had 45 people attend. He says 10 of those patients have started to use his medical practice, since he is (according to one of his new patients) “so far ahead of his original neurologist on new possible treatments for Parkinson’s disease”. Interestingly, he said most of his new patients had been with neurologists at major medical universities, where the people stated, “It is amazing that the university doctors are so cautious in their ways, that they will not even listen about what is new or seem to care about what is possible.”

Zhittya’s Outreach Program invites test subjects, believers, doctors, and clinics to join us in raising awareness, enhancing their practices, and helping patients tired of hearing “there is nothing we can do for you”. I will personally lead this effort to ensure its success. If interested, please email me at Dan333@aol.com. Let’s share our patients’ stories and help clinics enhance their medical practice.

Stroke: Clinical Description and Angiogenesis Therapy as a Possible Breakthrough Treatment Dr. Jacobs has written a White Paper on using our FGF-1 to enhance recovery from a stroke. Each year, 15 million people suffer strokes, resulting in 5 million deaths and 5 million permanently disabled survivors. Zhittya has treated five stroke patients with FGF-1, witnessing remarkable improvements that restored functionality to those once thought permanently impaired. There are 100 million stroke survivors living worldwide (often living with diabetes as well). This ranks stroke as the third-leading cause of death and suffering, following heart disease and cancer. Even though we only have a small sample size, our results with stroke offer hope and the inquiries we get about this treatment grow monthly.

Dr. Jacobs wrote this paper detailing FGF-1’s potential in stroke recovery, supported by an abundance of scientific data. Download it here: https://www.zgm.care/stroke My aunt survived a stroke but lived 12 years as a semi-vegetable, unable to feed herself or speak, and in constant pain. I’m proud of Dr. Jacobs’ work to use FGF-1 to diminish the pain and suffering of survivors of stroke and to enhance their recovery.

Vika Montano’s Patients’ Comments Section: Every month, I receive emails and phone calls from our test subjects. Here I have selected a few of their comments so you can read what those who have joined our Medical Research Studies are reporting to us.

Hello Vika, I want to share with you what has been happening with my health progress.

I had a very challenging 2024 dealing with chronic insomnia, which caused the PD symptoms to exacerbate. About six weeks ago I started experiencing dyskinesia.

When this happens, I know I must adjust the Mucuna Pruriens. When I went to the British Virgin Islands, I was taking 10g of the Mucuna, 2.5g four times a day. I am now taking 2g three times a day, that is a total of 6g per day! At the height of the PD symptoms, I was taking 18g per day. I have also been experiencing periods of free mobility more often now. I am now able to type with both hands without any hesitations, my left hand is no longer freezing. The tremors are gone. I am very hopeful that I will continue experiencing restored health. FGF-1 is working I’m sure of that; due to other health challenges that we may be facing it might take a bit longer to notice. I thank God for Zhittya’s team and the efforts that they put out day after day to bring this healing to all those suffering from neurological disorders. Thank you! Thank you! May God continue to bless all that you do!

With Gratitude,

Evelynn XXXXXX

#2: Hi, Vika.

Thanks for reaching out. Hope you are well.

Eager to receive and begin re-dose. I have successfully cut back on levodopa and plan to continue reducing intake. Thanks for all you do!

Best regards,

Ryan

Border Medical Tourism Cross Border Medical Tourism services are for those people who want to be considered for Zhittya’s future clinical trials or its current Medical Research Studies. Cross Border’s focus is to fill all available slots in the Medical Research Studies in the British Virgin Islands and The Bahamas, while we wait for other clinics to come online.

Cross Border is working on filling the available slots for the next BVI Medical Research Studies (intranasal FGF-1 for Parkinson’s disease) on the following dates:

Cohort #36: May 2, 2025 – May 7, 2025

Cohort #37: June 2, 2025 – June 7, 2025

Cohort #38: July 7, 2025 – July 12, 2025

I am showing cohorts further out in time since we are filling up faster and have fewer spots open each month.

Please contact Sam Cross at Cross Border Medical if you wish to be considered for the BVI cohorts or slots in The Bahamas. Sam’s email address is: sam.crossbordermedical@gmail.com.

In addition, if you are interested in participating in the brain scan studies which will take place at Washington University in St. Louis, please let Sam know. There are a finite number of slots for the imaging studies. These studies will look at brain blood flow before and after treatment with FGF-1. Upcoming Events Freedom Fest 2025 June 11 – 14 in Palm Springs, California Dr. Jacobs and I will both be presenting at the FreedomFest in June, which normally attracts many elected government officials. Last year, over 2,500 attendees attended. At the 2024 Freedom Fest, Robert Kennedy Jr. was the Keynote Speaker, and we were able to chat with him there.

Dr. Jacobs in his section below will discuss the concept of “endothelial cell dysfunction” and its role in initiating neurodegenerative diseases. He will also discuss the potential role of FGF-1 to reverse this dysfunction.

I will be speaking on the Main Stage about changing the Federal “Right to Try Law” and about how we are trying to get Nevada to spring forward on advancing medical innovation. I will be discussing how reasonable actions could accelerate medical innovation and provide a lower barrier to entrepreneurial medical innovators who do not have access to a billion dollars and a willingness to wait 18 years. I have seen amazing medical discoveries over the last 20 years that have not advanced because of the huge barrier of 1 to 2 billion dollars. Most of the medicines Big Pharma sells you today were developed 40 to 50 years ago. Imagine that without innovative competition, we would not have cell phones, smartphones, etc. The freedom to compete is what has made America great and its citizens prosperous!

Nevada legalized gambling in 1931 and turned its barren desert land into an economic miracle. I believe if Nevada legalizes people's right to try a medical innovation, to save their life or that of someone they love, it is their right. My life did not come to me from the government. I got the rights to my life and health from God!

Viktoriya Montano, Vice President of Strategic Innovations I have been working on the subject: Is FGF-1 a Treatment for Neuropathy?

Introduction

According to the National Institute of Health (NIH), peripheral neuropathy is currently an untreatable disease affecting 13.5% of the general US population aged 40 years or older.

Lower extremity peripheral neuropathy leads to diminished balance, falls, unnoticeable injuries and cuts to the feet that go neglected and, in turn, lead to chronic wounds and infections, which can lead to lower extremity amputations.

All these cases have the same underlying condition: dying or compromised blood vessels that supply nutrients and remove cellular waste products from those neurons. Currently, available treatments include heat compresses for trigeminal nerve neuropathy, surgery for carpal syndrome and trigeminal nerve neuropathy, and/or painkillers for the remaining neuropathies, which include lower extremity neuropathy.

The new approach by Zhittya Genesis Medicine is to reestablish blood flow to affected areas, regardless of their location. Currently, Zhittya Genesis Medicine is working with the therapeutic agent, FGF-1, a known growth factor that triggers the growth of new blood vessels.

The proposed treatment consists of injecting a solution of FGF-1 into the affected areas. The proposed Protocol for treating neuropathies has been established from previous work with FGF-1 in treating other medical conditions. It was later tried with one patient with neuropathy in the feet, induced by type 2 diabetes. At that time, only one foot was treated, while the other was left as a control.

Below is shown the graded foot of the patient divided into 26 squares.

The picture above demonstrates injection into the foot of the patient.

Injections were well tolerated by the patient, with only a few of the 26 injections resulting in pain to the patient. According to the patient, half of his foot did not feel anything prior to treatment, and he did not feel any prickling pain from the injections.

A biological response to the treatment normally can be seen by the next morning, but sometimes it can be delayed for another 24 hours. It depends on the area where the injections take place, and this was established in prior unrelated experiments. Biological response visually presents as swelling and redness of the injected area.

The patient’s treated foot showed pronounced swelling the day after treatment with the swelling completely subsiding after 5–7 days.

The biological response of swelling and redness is a normal response to trauma.

Except in this case, there was no acute traumatic event. However, the tissue affected by neuropathy and the lack of blood supply were primed to receive the angiogenesis promoting agent, just like what would happen during acute trauma.

FGF-1 molecules bind to the upregulated receptors on the starving cells and swelling and redness demonstrate that the drug is doing its job.

The individual reported a 70–80% decrease in pain in the treated foot after 4 weeks. The full picture of recovery should be more obvious in 3 months, as that timeline was established during our heart trial in US FDA-authorized clinical trials.

Currently, we believe that the treatment should consist of one-time injection/injections into the affected area.

After two months from the treatment, it is possible to see that the treated foot is slightly pinker than the untreated foot and the patient reports to have very little pain now in the treated foot. I believe we may have something very significant to change the treatment of neuropathy.

Dr. Jack Jacobs

As readers of this Update know, there is a growing body of evidence that vascular or blood flow issues may be an initiating event in many neurodegenerative brain disorders, including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and more. We and other medical researchers believe this lack of blood flow is caused by a defect in the vascular system of the brain where blood vessels in the brain become dysfunctional and “leaky”. This disorder is referred to as “endothelial cell dysfunction” and this problem with blood vessels is believed to be the underlying cause of many brain disorders.

All of the blood vessels in our bodies are lined with a single layer of endothelial cells. These flattened cells form the natural barrier between our circulatory system and outside tissues. The endothelial cells are permeable to small molecules such as oxygen, water and glucose, which is important, as this is the way our body nourishes all our living cells. However, larger molecules, such as red and white blood cells, immune cells, and proteins, cannot freely cross the endothelial cell barrier.

The picture below shows a normal, healthy artery that contains a single layer of endothelial cells along with multiple layers of smooth muscle cells that allow the artery to relax and constrict, thereby regulating the amount of blood that flows into a tissue or organ.

If the endothelial cell layer of a blood vessel becomes damaged as shown in the figure below, blood flow is decreased and adjacent tissues are potentially exposed to harmful substances in the blood (for example, enzymes, immune cells, blood clotting factors such as fibrinogen) that never should escape the blood vessels.

In the damaged vessel above on the right, fibrinogen, a clotting factor that forms fibrin clots escapes the blood vessel and can coat the outside of an adjacent neuron, making the neuron appear as “foreign” to the body and leading to an attack on the neuron by the body’s immune system.

Medical researchers have now implicated “endothelial cell dysfunction” in a number of medical disorders, including multiple sclerosis (MS), multi-infarct dementia, and more recently, MSA. There is excellent evidence that our very own FGF-1 can heal this endothelial cell dysfunction in an animal model of multiple sclerosis.

The figure below shows the inside of a blood vessel that was located within a multiple sclerosis lesion in the spinal cord of a mouse. The left side of the figure shows a blood vessel ravaged with endothelial cell dysfunction, where the endothelial cell layer has become damaged and deformed. As the animal is treated with FGF-1 over a 30-day period, a remarkable “healing” of the endothelial cell layer is evident at day 30 where the inside of the blood vessel is now filled with a well-ordered and healthy array of endothelial cells.

Results such as these support the belief that endothelial cell dysfunction is a prime culprit in the initiation and progression of multiple sclerosis and that factors which stimulate blood vessel repair, such as FGF-1, may be good therapeutic options to reverse the disease process. Given the excellent safety profile of FGF-1 which has been established in humans and the relative ease of delivery of FGF-1 into the brain, via intranasal delivery, it makes all the sense in the world to see if FGF-1 could have a beneficial effect in a host of other neurodegenerative diseases as well.

Conclusion by Dan Montano

This Update is very full, as we are advancing on many tasks at the same time.

Zhittya has many wonderful projects working to advance what, I believe, is the greatest medical breakthrough of the last 100 years. It is reported that 65% of all adults die from a disease which is caused by the lack of blood flow to a tissue or an organ. I believe FGF-1, with its ability to trigger new blood vessel growth, could defer death and suffering for 90% of those people. Zhittya has advanced below the radar for decades. I believe over the next 6 months, Zhittya must go on a “Full Court Press” to accomplish many important treatments. We have great data; however, our barrier is the USA FDA. I do not want to be deferred another ten years waiting for the FDA to respond to a cure for type-2 diabetes, because of all the money they get from Big Pharma. Big Pharma, known for dealing with the symptoms of disease; not the cause of the disease. I believe we have a “Window of Opportunity” to advance our medicines and get some approved sooner now that Washington DC is demanding “Common Sense” regulations. I believe our window of opportunity is 45 months. We need to make progress when we have the wind to our back. Zhittya has been quietly advancing and obtaining great human data. Now we must now “Charge into this battle and seek victory!”

This FGF-1 molecule was discovered over 40 years ago. It has been used by us and others in medical research and has been proven safe with amazing outcomes.

From deferring death from heart disease, to treating brain disorders, to diabetes, to neuropathy, and more, yet it has not reached the hundreds of millions of people who could have benefited from it had it been approved in the 1990s. Of the 17 million people who die of heart disease every year, I believe FGF-1 could have prevented the deaths of 85% of those people. From simple math, I will guess 14 million people per year could have been saved if FGF-1 had been approved in

1998. Today, 2025, it is 27 years later, and at 14 million people times 27 years, it is 370 million people whose lives we could have extended, if not for the rules of the FDA to protect those people from what, Life? They died because this medicine was trapped in a Byzantine Bureaucracy of delay, delay, delay.

We have 45 months to accomplish what has not been accomplished in 46 years, getting FGF-1 to sick humans.

Now, people! Now! We must rally and get the FDA to use common sense, making sick people suffer and die is not right. If we cannot get the Federal Government to care about its people's health and life, we will try and get Nevada to do it.

I pray we all succeed!

Bless you all!

Dan Montano, CEO

Zhittya Genesis Medicine

8683 W. Sahara Ave Suite 280

Las Vegas, NV 89117

USA zgm.care

<https://www.nevbio.org/>

[mailto:Dan333@aol.com](mailto:Dan333@aol.com)

<https://www.zgm.care/stroke>

[mailto:sam.crossbordermedical@gmail.com](mailto:sam.crossbordermedical@gmail.com)

<https://www.zgm.care/>